The N¹-methyladenosine methyltransferase TRMT61A promotes bladder cancer progression and is targetable by small molecule compounds

References

[1] Xia CF, Dong XS, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135:584-590.

[2] Patel VG, Oh WK, Galsky MD. treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404-423.

[3] Dominissini D, Nachtergaele S, Moshitch-Moshkovitz S, et al. The dynamic N(1)-methyladenosine methylome in eukaryotic messenger RNA. Nature. 2016;530:441-446.

[4] Xiong XX, Li X, Yi C. N(1)-methyladenosine methylome in messenger RNA and non-coding RNA. Curr Opin Chem Biol. 2018;45:179-186.

[5] Li X, Xiong X, Wang K, et al. Transcriptome-wide mapping reveals reversible and dynamic N(1)-methyladenosine methylome. Nat Chem Biol. 2016;12(5):311-316.

[6] Shi L, Yang XM, Tang DD, et al. Expression and significance of m¹A transmethylase, hTrm6p/hTrm61p and its related gene hTrm6/hTrm61 in bladder urothelial carcinoma. Am J Cancer Res. 2015;5(7):2169-2179.

[7] Monshaugen I, Luna L, Rhodes J, et al. Depletion of the m¹A writer TRMT6/TRMT61A reduces proliferation and resistance against cellular stress in bladder cancer. Front Oncol. 2024;13:1334112.

[8] Yin JJ, Song YL, Guo YF, et al. Transcriptome-wide 1-methyladenosine functional profiling of messenger RNA and long non-coding RNA in bladder cancer. Front Genet. 2024;15:1333931.

[9] Macari F, El-Houfi Y, Boldina G, et al. TRM6/61 connects PKCalpha with translational control through tRNAi(Met) stabilization: impact on tumorigenesis. Oncogene. 2016;35(14):1785-1796.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.